Biocon Limited has made a Qualified Institutions Placement of 13,63,63,635 equity shares amounting to ₹4,500 crore.
JSA Advocates and Solicitors represented Biocon Limited on this QIP
The transaction team was led by Madhurima Mukherjee Saha (Lead Partner), along with support from Equity Capital Markets team, including Sagar Batra (Partner), and Bhavini Mohan (Senior Associate), Aryaman Singh (Associate), Nidhi Prakriti (Associate), Rachit Munjal (Associate).
Cyril Amarchand Mangaldas advised the Book Running Lead Managers - Kotak Mahindra Capital Company Limited, BofA Securities India Limited, and Goldman Sachs (India) Securities Private Limited on this QIP.
The transaction team consisted of Yash J. Ashar (Senior Partner), Reuben Chacko (Partner, Regional Co-Head - Capital Markets - South), Tanvi Kini (Principal Associate), and Associates - Vishesh Jain, Bhaskar Kumar, Dhruv S, Tejaswi Sade and Zubin Ronnie.
Linklaters Singapore acted as International counsel to the BRLMs on this QIP and the team was led by Partner Amit Singh.
Biocon Limited is a leading biopharmaceutical company that develops, manufactures, and markets a wide range of healthcare products globally. Their focus areas include biosimilars, research services, and branded formulations.
This QIP is Biocon’s first equity fundraise since its initial public offering in 2004. The funds from this QIP will strengthen Biocon's ongoing research and development efforts, as well as expand global access to lifesaving biopharmaceuticals
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.